Related Experiment Video
Updated: May 21, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Targeting Huntington's disease through histone deacetylases
1Translational Cancer Research Group, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin 8, Ireland.
Clinical Epigenetics
|June 19, 2012
Summary
Huntington's disease (HD) involves abnormal protein modifications, impacting neurodegeneration. Targeting histone deacetylases offers a potential therapeutic strategy for this condition.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Huntington's disease (HD) is a severe neurodegenerative disorder with limited treatment options.
- Aberrant post-translational modifications (PTMs) of proteins are increasingly recognized in HD pathogenesis.
- PTMs like acetylation, phosphorylation, methylation, sumoylation, and ubiquitination are implicated.
Purpose of the Study:
- To review the evidence linking aberrant PTMs to Huntington's disease.
- To explore the role of cellular machinery regulating PTMs in HD.
- To discuss potential therapeutic strategies targeting PTM-regulating proteins.
Main Methods:
- Literature review of current evidence on PTMs in HD.
- Analysis of the role of protein families regulating PTMs.
- Examination of therapeutic potential of targeting histone deacetylases.
Main Results:
- Aberrant PTMs are significantly associated with HD pathogenesis.
- Dysregulation of PTM-modulating cellular machinery contributes to HD.
- Histone deacetylases represent a promising therapeutic target.
Conclusions:
- Targeting aberrant PTMs and their regulatory proteins is crucial for HD treatment.
- Pharmacological inhibition of histone deacetylases shows therapeutic promise for Huntington's disease.
- Further research into PTMs could unveil novel treatment avenues for HD.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:32Histone Modification
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...